Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 4:15 PM ET
Citius Pharmaceuticals Inc (CTXR) Stock Chart
Citius Pharmaceuticals (CTXR) has a latest price of $0.52 on Nov 17, 2026, 66.3% below its 52-week high of $1.54. Its price fell 47.0% over the past 12 months. The month-end price fell 99.6% since Jul 2017, a compound annual decline of 44.9%.
Price Chart
From Jul 2017 to Oct 2026, its highest month-end close was $130.75 in Jul 2017 and its lowest $0.52 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart CTXR with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for CTXR.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 18.6%, and over 6 months it fell 6.4%. The month-end price fell 97.2% over the 3 years through Oct 2026, a compound annual decline of 69.7%.
| Period | Change |
|---|---|
| 1 month | +21.3% |
| 3 months | -18.6% |
| 6 months | -6.4% |
| 12 months | -47.0% |
| 12 months, with dividends | -47.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -97.2% | -69.7% |
| 5 years | -98.9% | -59.3% |
| Since Jul 2017 | -99.6% | -44.9% |
Price by Year
Its best calendar year was 2021, when the price rose 51.0%, and its weakest was 2025, when it fell 80.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $0.52 | -32.7% |
| 2025 | $0.78 | -80.6% |
| 2024 | $4.00 | -78.8% |
| 2023 | $18.91 | -4.2% |
| 2022 | $19.75 | -48.7% |
| 2021 | $38.50 | +51.0% |
| 2020 | $25.50 | 0.0% |
| 2019 | $25.50 | -1.9% |
| 2018 | $26.00 | -72.6% |
Trading Range
The price is 0.5% below its 50-day average of $0.52 and 19.0% below its 200-day average of $0.64.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $0.52 | |
| 52-week high | $1.54 | -66.3% |
| 52-week low | $0.37 | +40.2% |
| 50-day average | $0.52 | -0.5% |
| 200-day average | $0.64 | -19.0% |
Price Risk
Over 3 years, its largest fall from a peak was 98.6%.
| Measure | Value |
|---|---|
| 1-year beta | 1.92 |
| Largest fall, 1 year | -74.3% |
| Largest fall, 3 years | -98.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About CTXR
What is CTXR's 1-year price change?
Citius Pharmaceuticals's price fell 47.0% over the past 12 months. With dividends included, the 12-month total return was -47.0%.
What is CTXR's 5-year price change?
Citius Pharmaceuticals's month-end price fell 98.9% over the 5 years through Oct 2026, a compound annual decline of 59.3%. These figures leave out dividends.
What is CTXR's 52-week high and low?
Citius Pharmaceuticals's 52-week high is $1.54 and its 52-week low is $0.37. Its latest price of $0.52 on Nov 17, 2026 is 66.3% below the high.
What is CTXR's beta?
Citius Pharmaceuticals's 1-year beta against the S&P 500 is 1.92, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 74.3%.
Is the CTXR chart free?
Yes. Advanced Charting for CTXR is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
CTXR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors